Improving clinical outcomes in treating heroin dependence: Randomized, controlled trial of oral or implant naltrexone

Archives of General Psychiatry

Volumn 66, Issue 10, 2009, Pages 1108-1115

  Hulse, Gary K ^a   Morris, Noella ^a   Arnold Reed, Diane ^a,b   Tait, Robert J ^a,c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF NOTRE DAME   (Australia)

^c AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOMA; HEROIN DEPENDENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; RANDOMIZED CONTROLLED TRIAL; SURGICAL INCISION SITE PAIN; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME; VOMITING; WOUND HEMATOMA;

ADMINISTRATION, ORAL; ADULT; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HEROIN DEPENDENCE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RECURRENCE; SUBSTANCE ABUSE DETECTION; TABLETS; TREATMENT OUTCOME;

EID: 70349667302     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2009.130     Document Type: Article

References (34)

1. Brewer C. Serum naltrexone and 6-β-naltrexol levels from naltrexone implants can block very large amounts of heroin: a report of two cases. Addict Biol. 2002;7(3):321-323. (Pubitemid 34848420)
2. Chiang CN, Hollister LE, Gillespie HK, Foltz RL. Clinical evaluation of a naltrexone sustained-release preparation. Drug Alcohol Depend. 1985;16(1):1-8. (Pubitemid 16256171)
3. Navaratnam V, Jamaludin A, Raman N, Mohamed M, Mansor SM. Determination of naltrexone dosage for narcotic agonist blockade in detoxified Asian addicts. Drug Alcohol Depend. 1994;34(3):231-236. (Pubitemid 24091669)
4. Verebey K, Volavka J, Mule SJ, Resnick RB. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther. 1976;20(3):315-328.
5. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD001333. doi:10.1002/14651858.CD001367.
6. Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs. 2007;16(8):1285-1294. (Pubitemid 47317017)
7. Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O'Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-218. (Pubitemid 43213883)
8. Ngo HT, Arnold-Reed DE, Hansson RC, Tait RJ, Hulse GK. Blood naltrexone levels over time following naltrexone implants. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(1):23-28.
9. Hulse GK, Low VH, Stalenberg V, Morris N, Thompson RI, Tait RJ, Phan CT, Ngo HT, Arnold-Reed DE. Biodegradability of naltrexone-poly(DL) lactide implants in vivo assessed under ultrasound in humans. Addict Biol. 2008;13(3-4):364-372.
10. Hulse GK, Stalenberg V, McCallum D, Smit W, O'Neil G, Morris N, Tait RJ. Histological changes over time around the site of sustained-release naltrexone-poly (DL-lactide) implants in humans. J Control Release. 2005;108(1):43-55. (Pubitemid 41476673)
11. National Health and Medical Research Council. National Statement on Ethical Conduct in Human Research 2007. http://www.nhmrc.gov.au/publications/ ethics/2007-humans/contents.htm. Accessed July 13, 2009.
12. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R, O'Neil P. Blood naltrexone and 6-β-naltrexol levels following naltrexone implant: comparing two naltrexone implants. Addict Biol. 2004;9(1):59-65. (Pubitemid 38608487)
13. Hulse GK, Basso MR. The association between naltrexone compliance and daily supervision. Drug Alcohol Rev. 2000;19:41-48.
14. Darke S, Ward J, Hall W, Heather N, Wodak A. The Opiate Treatment Index (OTI) Researchers' Manual. Sydney, Australia: National Drug and Alcohol Research Centre; 1991. Technical Report No. 11.
15. Hansson R, Toh E. Free Naltrexone and 6-β-Naltrexol in Whole Blood by LC-MS-MS. Perth, Australia: Chemistry Centre; 2000.
16. Therapeutic Goods Administration. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). Canberra, Australia: Commonwealth Department of Health and Aged Care; 2000.
17. Therapeutic Goods Administration. Note for Guidance on Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95). Canberra, Australia: Commonwealth Department of Health and Aging; 2000.
18. Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med. 1979;9(1):139-145.
19. Digiusto E, Panjari M, Gibson A, Rea F; NEPOD Research Group. Follow-up difficulty: correlates and relationship with outcome in heroin dependence treatment in the NEPOD study. Addict Behav. 2006;31(7):1201-1210. (Pubitemid 43913368)
20. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmacoeconomics. 2005;23(1):77-91. (Pubitemid 40194011)
21. Fishman M. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction. 2008;103(8):1399-1401. (Pubitemid 352009050)
22. Kruptisky EM, Burakov AM, Tsoy MV, Egorova VY, Slavina TY, Grinenko AY, Zvartau EE, Woody GE. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction. 2007;102(7):1164-1165.
23. Hulse GK, O'Neil G, Hatton M, Paech M. Use of oral and implantable naltrexone in the management of the opioid-impaired physician. Anaesth Intensive Care. 2003;31(2):196-201. (Pubitemid 36503835)
24. Hulse GK, Arnold-Reed DE, O'Neil G, Chan CT, Hansson R. Achieving long-term continuous blood naltrexone and 6-β-naltrexol coverage following sequential naltrexone implants. Addict Biol. 2004;9(1):67-72. (Pubitemid 38608488)
25. Waal H, Frogopsahl G, Olsen L, Christophersen AS, Mørland J. Naltrexone implants: duration, tolerability and clinical usefulness. Eur Addict Res. 2006;12(3):138-144. (Pubitemid 43909807)
26. Oncken C, Van Kirk J, Kranzler HR. Adverse effects of oral naltrexone: analysis of data from two clinical trials. Psychopharmacology (Berl). 2001;154(4):397-402. (Pubitemid 32260899)
27. Galloway G, Koch M, Cello R, Smith D. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial. BMC Psychiatry. 2005;5:18. doi:10.1186/1471-244X-5-18. (Pubitemid 41460708)
28. Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW; Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617-1625. (Pubitemid 40471792)
29. Johnson BA, Ait-Daoud N, Aubin H-J, van den Brink W, Guzzetta R, Loewy J, Silverman B, Ehrich E. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res. 2004;28(9):1356-1361. (Pubitemid 39238294)
30. Swainston Harrison T, Plosker GL, Keam SJ. Extended-release intramuscular naltrexone. Drugs. 2006;66(13):1741-1751.
31. Ngo HTT, Tait RJ, Hulse GK. Comparing drug-related hospital morbidity following heroin dependence treatment with methadone maintenance or naltrexone implant. Arch Gen Psychiatry. 2008;65(4):457-465.
32. Digiusto E, Shakeshaft A, Ritter A, O'Brien S, Mattick RP; NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99(4):450-460. (Pubitemid 38496661)
33. San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict. 1991;86(8):983-990.
34. Anton RF, Hogan I, Jalali B, Riordan CE, Kleber HD. Multiple family therapy and naltrexone in the treatment of opiate-dependence. Drug Alcohol Depend. 1981;8(2):157-168. (Pubitemid 12252469)